News

Genotyping and artificial intelligence are together starting to predict the progression of glaucoma in individual patients, sparing them from suboptimal treatments and adverse effects. Recent research efforts are exploring modifiable risk factors such as caffeine consumption.

After a brief hiatus during the pandemic, the Flying Eye Hospital program returns.

The destination of Marco Island, Florida not only serves as an excellent backdrop for this year's Ophthalmology Times® EyeCon 2022 but also provides a unique opportunity for family members to see their ophthalmic loved ones in a professional light.

Anti-VEGF biosimilars may offer a therapeutic alternative to the original biologic because they have the ability to lower the overall therapeutic cost in the management of varied chorioretinal disorders.

Let us know if you will plan to use biosimilars in your daily practice. The poll will be open until October 10, 2022.

The American Academy of Ophthalmology will hold its annual meeting beginning Friday at McCormick Place in Chicago.

Although it is always important to consider optimizing the ocular surface for all patients to improve their vision, it is of critical importance before cataract surgery.

According to Nicole Fram, MD, around the world, corneal specialists are making the most of limited resources.

The Florida Second District Court of Appeal has renewed a woman’s lawsuit claiming she suffered permanent eye damage when her ophthalmologist misdiagnosed her during nasal surgery. In its opinion, the appellate court ruled that the trial court erred when it dismissed the lawsuit.

The advanced swept-source OCT technology allows visualization of the variations in the normal changes and those associated with aging in the posterior vitreous.

The treatment of vision problems can help improve the quality of life for many people in the city.

Fluocinolone acetonide intravitreal implant or faricimab (6.0 mg) injections versus observation will be studied for the prevention of visual acuity loss due to radiation retinopathy

Jeremy Tan, MD, discusses the latest trends in eye trauma surgery at the Dean McGee Eye Institute.

Coherus BioSciences’ ranibizumab-eqrn is the first and only FDA-approved biosimilar interchangeable with ranibizumab injection for all indications, with 12 months of interchangeability exclusivity.

NYU Langone Health has been recognized as No. 1 in quality and safety for inpatient and ambulatory care by Vizient Inc.

Co-chairs Peter J. McDonnell, MD, director of the Wilmer Eye Institute at Johns Hopkins University School of Medicine in Baltimore, Maryland, and Oluwatosin U. Smith, MD, of Glaucoma Associates of Texas in Dallas break down the top reasons to attend this year's Ophthalmology Times® EyeCon 2022 in a series of video segments.

Provectus will have an exclusive worldwide license of intellectual property developed by the Ophthalmic Biophysics Center of the Bascom Palmer Eye Institute.

The authors noted that the proportion of patients losing fewer than 15 letters from the baseline BCVA score in the study eye was comparable between the two groups.

The clinical trial is examining the efficacy of two doses of UBX1325 compared to every other month treatment with aflibercept through 24 weeks.

A powerful conversation about expectations can open communication and trust.

According to Nicox SA, the patients made their final 3-month visit last week. Topline results of the trial are expected in November.

Faricimab simultaneously targets and inhibits two disease pathways involving Ang-2 and VEGF-A linked to a number of vision-threatening retinal conditions.

Elizabeth Yeu, MD, will highlight pearls for managing intraocular lenses in difficult cases.

The Eye Center at UC Davis Health has two new endowed chairs focused on glaucoma, thanks to a $4 million donation from business entrepreneur Daryl Geweke.

Ophthalmologists should instruct their patients to pay attention to their eye health for the long term.

In AMD research, the experimental animals used are often young male mice. This is not optimal for the development of new treatments, as the disease most often affects the elderly – and women.

Cataract density and the fragmentation pattern the surgeon uses may influence the amount of ultrasound energy used for phacoemulsification and EPT.

Claes H. Dohlman, MD, PhD, widely considered the father of modern cornea science, is a recipient of the 2022 António Champalimaud Vision Award. The award, considered the “Nobel Prize of Vision," comes with a $1 million prize .